GlassScriptPhysician profile
Karen E Johnson
NPI 1720296916
$1,959.61
in general payments reported to CMS, 2019-2025
15 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $239 · 2023: $214 · 2024: $434 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.19 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.63 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $217.16 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $177.33 | 2022-2025 | |
| Novo Nordisk INC | $169.74 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $142.10 | 2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $99.50 | 2023 | Quviviq |
| Genentech USA, INC. | $62.34 | 2021 | |
| Glaxosmithkline, LLC. | $53.46 | 2022-2025 | Trelegy Ellipta |
| Biogen, INC. | $49.99 | 2025 | Skyclarys |
| Verona Pharma, INC. | $29.59 | 2025 | Ohtuvayre |
| Sumitomo Pharma America, INC. | $28.44 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $22.35 | 2025 | Capvaxive |
| United Therapeutics Corporation | $19.27 | 2021 | |
| Viatris Specialty LLC | $17.52 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.